Personalized Radiation Therapy for GBM

Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy

The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.

Inclusion Criteria:

• Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen
• Age 18 or older
• Ability to give signed informed consent
• Karnofsky Performance Status (KPS) at least 70

Exclusion Criteria:

• Placement of Gliadel wafers
• Participation in another investigational trial
• Active treatment of another malignancy